Plain-English translation of NCT03025477 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing two different ways to deliver chemotherapy to people with advanced ovarian cancer. One approach uses traditional intravenous (IV) chemotherapy with carboplatin and paclitaxel. The other uses cisplatin and epirubicin, with cisplatin sometimes delivered directly into the abdomen (called intraperitoneal chemotherapy) rather than through the vein. Researchers want to see which approach helps patients live longer and feel better.
Advanced ovarian cancer is a serious disease, and doctors need better ways to treat it in the first round of chemotherapy. This medication combination given directly into the abdomen may reach cancer cells more effectively, but researchers need to compare it directly with the standard intravenous approach to know if it's truly better for patients.
You likely qualify if…
You likely don't qualify if…
After your surgery, you will be randomly assigned to receive one of the two chemotherapy approaches. Both involve 6 cycles of chemotherapy given over about 18 weeks (one cycle every 3 weeks). In the experimental arm, you may also have a second surgery between cycles 3 and 4 if your doctors think it would help and you're healthy enough. You'll have regular blood tests and checkups to monitor your health and how well the treatment is working.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
France